ISRCTN97330959招募中3 期
Triple Negative Trial: a randomised phase III trial of carboplatin compared to docetaxel for patients with advanced oestrogen receptor-progesterone receptor-human epidermal growth factor receptor two-breast cancer
Institute of Cancer Research and King's College London (UK)0 个研究点目标入组 400 人开始时间: 2007年3月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29713086
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Histologically confirmed ER-, PR-, primary breast cancer (Allred less than three or H score less than ten or ER- and PR- negative, if other cut-offs used [e.g., 1%, 5% or 10%])
- •2. Histologically confirmed HER2- primary breast cancer (ImmunoHistoChemistry [IHC] scoring 0 or 1+ for HER2 or non-amplified for HER2 [Fluorescence In Situ Hybridisation {FISH}])
- •3. Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for local therapy
- •4. Patients with stable, treated brain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present
- •5. Eastern Cooperative Oncology Group (ECOG) performance status zero, one or two
- •6. Adequate haematology, biochemical indices (Full Blood Count [FBC], Urea and Electrolytes [U & Es])
- •7. Liver Function Tests (LFTs): normal bilirubin, Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) less than or equal to 3 x Upper Limit of Normal (ULN) if Alkaline Phosphatase is greater than 5 x ULN (or an isolated elevation AST/ALT of less than or equal to 5 x ULN)
- •8. Adequate renal function
- •9. Written informed consent, able to comply with treatment and follow-up
排除标准
- •1. Original primary tumour or subsequent relapse known to be positive for any of ER, PR, or HER2 receptors
- •2. Patients with inoperable locally advanced disease suitable for local radiotherapy or an anthracycline containing regimen
- •3. Patients unfit for chemotherapy or those with neuropathy greater than grade one (sensory or motor)
- •4. Known allergy to platinum compounds or to mannitol
- •5. Known sensitivity to taxanes
- •6. Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry
- •7. Previous treatment with a taxane for recurrent/metastatic disease
- •8. Previous treatment with a platinum chemotherapy drug
- •9. LFTs: abnormal bilirubin (greater than ULN), AST and/or ALT greater than 3 x ULN and Alkaline Phosphatase greater than 5 x ULN (or an isolated elevation AST/ALT of greater than or equal to 5 x ULN)
- •10. Patients with a life expectancy of less than three months
- •11. Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease free interval of at least ten years
- •12. Patients with bone limited disease
- •13. Other serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy and/or the completion of trial therapy
- •14. Pregnant, lactating or potentially childbearing women not using adequate contraception (documentation of a negative serum Human Choronic Gonadotropin [HCG] pregnancy test should be available for pre-menopausal women with intact reproductive organs, or women less than two years after the menopause. Fertile women and their partners must use a medically acceptable contraceptive throughout the treatment period and for six months following cessation of treatment. Subjects must be made aware before entering the trial of the risk in becoming pregnant)
研究者
相似试验
已完成
不适用
Standard open radical cystectomy (ORC) versus robotically assisted radical cystectomy (RARC)Malignant neoplasm of bladderCancerBladder cancerISRCTN13680280niversity College London338
终止
3 期
HYMN: a trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come backCancerISRCTN85785327niversity College London (UK)242
已完成
3 期
Clinical trial to assess the importance of nephrectomyMetastatic renal cell carcinoma, clear cell carcinoma (the most common type of renal cell carcinoma).Malignant neoplasm of kidney, except renal pelvisCancerISRCTN19562321HS Greater Glagsow and Clyde (UK)450
已完成
3 期
Gemcitabine and Docetaxel versus Doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue SarcomasCancerISRCTN07742377niversity College London (UCL) (UK)250
已完成
不适用
A study evaluating three treatments for foot callusISRCTN14751843niversity of Salford (UK)60